IMMUNOLOGICAL MECHANISMS OF RESISTANCE TO CDK4/CDK6 INHIBITORS IN BREAST CANCER

被引：1
|
作者：
Petroni, Giulia [1 ]
Gouin, Kenneth [2 ]
Martinez, Aitziber Buque [1 ]
Knott, Simon [2 ]
Formenti, Silvia [1 ]
Galluzzi, Lorenzo [1 ,3 ]
机构：
[1] Weill Cornell Med Coll, Brooklyn, NY USA
[2] Cedars Sinai, Los Angeles, CA USA
[3] Weill Cornell Med, New York, NY USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷
关键词：
D O I：
10.1136/jitc-2021-SITC2021.733
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
733
引用
收藏
页码：A763 / A763
页数：1
相关论文
共 50 条
  • [1] CDK6 overexpression promotes resistance to CDK4/6 inhibitors in breast cancer
    Li, Qing
    Razavi, Pedram
    Li, Zhiqiang
    Paula, Arnaud F. Da Cruz
    Brogi, Edi
    Scaltriti, Maurizio
    Reis-Filho, Jorge S.
    Chandarlapaty, Sarat
    CANCER RESEARCH, 2019, 79 (13)
  • [2] Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment
    Glaviano, Antonino
    Wander, Seth A.
    Baird, Richard D.
    Yap, Kenneth C. -H.
    Lam, Hiu Yan
    Toi, Masakazu
    Carbone, Daniela
    Geoerger, Birgit
    Serra, Violeta
    Jones, Robert H.
    Ngeow, Joanne
    Toska, Eneda
    Stebbing, Justin
    Crasta, Karen
    Finn, Richard S.
    Diana, Patrizia
    Vuina, Karla
    de Bruin, Robertus A. M.
    Surana, Uttam
    Bardia, Aditya
    Kumar, Alan Prem
    DRUG RESISTANCE UPDATES, 2024, 76
  • [3] Resistance mechanisms and therapeutic strategies of CDK4 and CDK6 kinase targeting in cancer
    James J. Asciolla
    Xuewei Wu
    Christos Adamopoulos
    Evripidis Gavathiotis
    Poulikos I. Poulikakos
    Nature Cancer, 2025, 6 (1) : 24 - 40
  • [4] Targeting CDK4 and CDK6 in cancer
    Goel, Shom
    Bergholz, Johann S.
    Zhao, Jean J.
    NATURE REVIEWS CANCER, 2022, 22 (06) : 356 - 372
  • [5] Targeting CDK4 and CDK6 in cancer
    Shom Goel
    Johann S. Bergholz
    Jean J. Zhao
    Nature Reviews Cancer, 2022, 22 : 356 - 372
  • [6] CDK4 and CDK6 Inhibition in Breast Cancer - A New Standard
    Wolff, Antonio C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (20): : 1993 - 1995
  • [7] Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review
    Pandey, Kamal
    An, Hee-Jung
    Kim, Seung Ki
    Lee, Seung Ah
    Kim, Sewha
    Lim, Sun Min
    Kim, Gun Min
    Sohn, Joohyuk
    Moon, Yong Wha
    INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (05) : 1179 - 1188
  • [8] Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
    Yang, C.
    Li, Z.
    Bhatt, T.
    Dickler, M.
    Giri, D.
    Scaltriti, M.
    Baselga, J.
    Rosen, N.
    Chandarlapaty, S.
    ONCOGENE, 2017, 36 (16) : 2255 - 2264
  • [9] Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
    C Yang
    Z Li
    T Bhatt
    M Dickler
    D Giri
    M Scaltriti
    J Baselga
    N Rosen
    S Chandarlapaty
    Oncogene, 2017, 36 : 2255 - 2264
  • [10] Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer
    Martin, Miguel
    Garcia-Saenz, Jose A.
    Manso, Luis
    Llombart, Antonio
    Cassinello, Alejo
    Atienza, Manuel
    Ringeisen, Francois
    Ciruelos, Eva
    FUTURE ONCOLOGY, 2020, 16 (33) : 2763 - 2778
12345